aXichem presents its powerful innovative ingredient, aXivite, at Expo West in the U.S., together with its partner SEE Nutrition
aXichem AB (publ), (aXichem), a developer of natural analogue industrial compounds, participates in Expo West held at Anaheim Convention Center in Ca, U.S, 7 – 11 March, 2023, presenting its innovative natural analogue phenylcapsaicin product aXivite® together with the company’s partner SEE Nutrition.
“Expo West is an excellent event for aXichem and a great opportunity to display the success of our product in the U.S. market. aXivite has been well received by producers and consumers and our recent news about aXivite being part of Hydroxycut, America's #1 selling weight loss supplement brand, has strengthened its position even further. Being part of the offer at major retailers in North America, such as Walmart, Target and GNC shows that aXichem is here to stay,” says Lucas Altepost, VP and VP Sales and Marketing at aXichem.
Find out more about aXivite in booth #3571 where we are represented by SEE Nutrition
The North American market for nutritional supplements intended for sports and fitness is expected to grow by an average of just over 6% during the period 2021-2026 according to MordorIntelligence.com. What is driving the growth is an increased awareness of health and a healthy lifestyle, but also that more training centers are being opened and that consumers' knowledge of nutritional supplements has increased.
The information was submitted, through the care of the contact person, for publication on 7 March 2023, at 10:30 AM CEST.
Torsten Helsing, CEO, aXichem, Ph+46 70 686 33 55. Email: [email protected]
aXichem’s business idea is to develop, patent and market natural analogue industrial compounds. The Company primarily works with phenylcapsaicin a structural analogue of capsaicin with a wide range of applications, such as feed additives, nutraceuticals and certain pharmaceutical areas. aXichem’s shares are listed on NASDAQ First North Growth Market under AXIC A. Certified Adviser: Västra Hamnen Corporate Finance, www.vhcorp.se. Read more about aXichem at www.axichem.se
Studie med gentestet Prostatype® publicerat i ledande internationell tidskrift
Studien som genomförts av ett forskningsteam på Akademiska sjukhuset i Uppsala under ledning av docent och överläkare Michael Häggman visar att gentestet Prostatype® korrekt bedömer prostatacancertumörens aggressivitet när man jämför genuttryck från vävnadsprover, så kallade biopsier, med ”fac...
ViroGates announces its Annual Report 2022: Growing revenue by 33% and more than tripling the customer base in clinical routine
BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, announces its Annual Report for the period 1 January – 31 December 2022, as approved today by the company’s Board of Directors....
AegirBio AB: Atlas Special Opportunities, LLC calls for partial conversion of outstanding convertible bonds to a nominal amount of MSEK 10.00
On 20 December 2022 AegirBio AB (“AegirBio” or the “Company”) announced that the Company had agreed on a convertible financing agreement with Atlas Special Opportunities, LLC (“Atlas”) regarding convertible bonds amounting to MSEK 55.00 (the “Convertible Bonds”) with attached warrants. On 20Ja...
AegirBio AB: Atlas Special Opportunities, LLC påkallar partiell konvertering av utestående konvertibler till ett nominellt belopp om 10,00 MSEK
Den 20 december 2022 meddelade AegirBio AB (”AegirBio” eller ”Bolaget”) att Bolaget avtalat om en konvertibelfinansiering med Atlas Special Opportunities, LLC (”Atlas”) avseende konvertibler om 55,00MSEK (”Konvertiblerna”) med vidhängande teckningsoptioner. Bolagsstämman beslutade den 20...